A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma

Overview of attention for article published in Digestive Diseases and Sciences, July 2019

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter: 3 X users

patent: 1 patent

Citations

dimensions_citation: 16 Dimensions

Readers on

mendeley: 28 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 3,056 followers.

Tucker et al from Georgetown University used the CCK antagonist proglumide in a mouse model of NASH and CCK, reporting the remarkable finding that reversed hepatic inflammation, fibrosis, and steatosis while preventing HCC development. https://t.co/SKohQ

10 Apr 2020

Reply Repost Favourite

RT @DrJHK: A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma https://t.co/RWrH…

12 Jan 2020

Reply Repost Favourite

A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma https://t.co/RWrHoP5vsr

11 Jan 2020

Reply Repost Favourite

A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma. https://t.co/fJRJS1Ke08

13 Jul 2019

Reply Repost Favourite